iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Rating) – Wedbush issued their FY2027 earnings estimates for iTeos Therapeutics in a report issued on Wednesday, March 15th. Wedbush analyst D. Nierengarten forecasts that the company will post earnings of ($6.43) per share for the year. Wedbush currently has a “Outperform” rating and a $33.00 target price on the stock. The consensus estimate for iTeos Therapeutics’ current full-year earnings is ($4.30) per share.
Several other research analysts have also recently issued reports on the stock. JPMorgan Chase & Co. dropped their target price on shares of iTeos Therapeutics from $34.00 to $32.00 and set an “overweight” rating on the stock in a report on Thursday. HC Wainwright reaffirmed a “buy” rating and issued a $54.00 price objective on shares of iTeos Therapeutics in a research report on Friday.
iTeos Therapeutics Stock Down 4.4 %
Institutional Investors Weigh In On iTeos Therapeutics
Institutional investors have recently added to or reduced their stakes in the stock. Point72 Hong Kong Ltd acquired a new stake in iTeos Therapeutics in the 1st quarter valued at $67,000. Ensign Peak Advisors Inc purchased a new position in iTeos Therapeutics in the 1st quarter valued at $73,000. Quantbot Technologies LP purchased a new position in iTeos Therapeutics in the 2nd quarter valued at $69,000. Mutual of America Capital Management LLC lifted its holdings in iTeos Therapeutics by 17.4% in the 2nd quarter. Mutual of America Capital Management LLC now owns 3,402 shares of the company’s stock valued at $70,000 after purchasing an additional 505 shares in the last quarter. Finally, Virtus ETF Advisers LLC lifted its holdings in iTeos Therapeutics by 39.1% in the 2nd quarter. Virtus ETF Advisers LLC now owns 5,790 shares of the company’s stock valued at $119,000 after purchasing an additional 1,629 shares in the last quarter.
About iTeos Therapeutics
Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.
- Get a free copy of the StockNews.com research report on iTeos Therapeutics (ITOS)
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
- Europe Raises Interest Rates, Should the Fed Follow?
Receive News & Ratings for iTeos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iTeos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.